Ascendis Pharma A/S (ASND)
120.97
-1.83
(-1.49%)
USD |
NASDAQ |
May 17, 16:00
120.97
0.00 (0.00%)
After-Hours: 20:00
Ascendis Pharma Cash from Investing (TTM): 91.67M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 91.67M |
December 31, 2023 | 310.14M |
September 30, 2023 | 306.78M |
June 30, 2023 | 294.42M |
March 31, 2023 | 248.10M |
December 31, 2022 | 65.10M |
September 30, 2022 | -69.43M |
June 30, 2022 | -56.25M |
March 31, 2022 | -51.29M |
December 31, 2021 | -130.83M |
September 30, 2021 | -73.63M |
June 30, 2021 | -86.30M |
March 31, 2021 | -362.07M |
December 31, 2020 | -332.56M |
September 30, 2020 | -258.64M |
June 30, 2020 | -271.91M |
March 31, 2020 | -9.748M |
December 31, 2019 | -5.776M |
September 30, 2019 | -5.762M |
Date | Value |
---|---|
June 30, 2019 | -5.728M |
March 31, 2019 | -5.806M |
December 31, 2018 | -3.127M |
September 30, 2018 | -2.081M |
June 30, 2018 | -0.9438M |
March 31, 2018 | -0.7894M |
December 31, 2017 | -1.066M |
September 30, 2017 | -0.9375M |
June 30, 2017 | -0.9242M |
March 31, 2017 | -0.9931M |
December 31, 2016 | -0.7437M |
September 30, 2016 | -1.038M |
June 30, 2016 | -0.962M |
March 31, 2016 | -1.208M |
December 31, 2015 | -1.153M |
September 30, 2015 | -0.8048M |
June 30, 2015 | -0.7758M |
March 31, 2015 | -0.4644M |
December 31, 2014 | -0.5386M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-362.07M
Minimum
Mar 2021
310.14M
Maximum
Dec 2023
-20.19M
Average
-30.52M
Median
Cash from Investing (TTM) Benchmarks
Evaxion Biotech AS | -- |
Biodexa Pharmaceuticals Plc | -0.3289M |
TC BioPharm (Holdings) PLC | -0.2614M |
Genmab A/S | -394.15M |
NuCana PLC | 3.594M |